Pharmaceutical Market in Australia:
The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms. View Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-australia-report.html
Headline Expenditure Projections
- Pharmaceuticals: AUD12.85bn (US$13.27bn) in 2011 to AUD13.07bn (US$13.59bn) in 2012; +1.6% in local currency terms and +2.4% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with Q412.
- Healthcare: AUD122.27bn (US$126.22bn) in 2011 to AUD127.37bn (US$132.47bn) in 2012; +4.2% in local currency terms and +5.0% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with previous quarter.
- Medical Devices: AUD5.57bn (US$5.75bn) in 2011 to AUD5.82bn (US$6.05bn) in 2012; +4.4% in local currency terms and +5.2% in US dollar terms due to exchange rate fluctuations. Forecast broadly in line with Q412.
Pharmaceutical Market in Mexico:
The improving regulatory environment and the increasing foreign direct investment make Mexico's pharmaceutical market more attractive to multinational drugmakers. We project an increase in government healthcare spending to further boost the number of procedures and expand access to medicines in its national health insurance programme. However, the potential deceleration of the country's macroeconomic growth may dampen the country's pharmaceutical market prospects. Generic drug competition and counterfeit medicines are also key concerns for multinationals pharmaceutical companies. View Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-mexico-report.html
Headline Expenditure Projections
- Pharmaceuticals: MXN161.45bn (US$12.99bn) in 2011 to MXN175.82bn (US$13.47bn) in 2012; +8.9% in local currency terms and +3.7% in US dollar terms. Forecasts increasefromQ4 12 due tomacroeconomic factors.
- Healthcare: MXN872.57bn (US$70.21bn) in 2011 to MXN951.98bn (US$72.95bn) in 2012; +9.1% in local currency terms and +3.9 % in US dollar terms. Forecastsincrease from Q4 12 due tomacroeconomic factors.
- Medical devices: MXN52.05bn (US$4.19bn) in 2011 to MXN57.85bn (US$4.43bn) in 2012; +11.1% in local currency terms and +5.9% in US dollar terms. Forecastsincrease from Q4 12 due tomacroeconomic factors.
Browse More Reports related to Pharmaceutical: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
The revival of the THB30 healthcare scheme in September 2012 will do little to ease the financial burden the government is facing as a result of the universal healthcare scheme. Nor will it solve existing issues such as the shortage of medical professionals and hospital overcrowding, given that these problems existed when the scheme was first implemented. We highlight that universal healthcare coverage will prove to be financially unsustainable in the long term, due to various factors - including Thailand's ageing population (and therefore increased burden of non-communicable diseases), medical tourism and the creation of the region-wide ASEAN Economic Community 2015 that is leading to the exit of medical professionals from Thailand 's public health sector.
We acknowledge the Nigerian government's endeavours to crack down on counterfeit drugs and reduce medical tourism out of the country, in addition to achieving, in our view, the overly ambitious goal of relaunching the National HIV Vaccine Plan. However, BMI maintains that the government needs to address fundamental issues in the healthcare sector as a first priority. Poor infrastructure, a brain drain of health professionals and inadequate funding of the public system mean enrolment in the sector will continue to be slow, hindering growth in the market. In the pharmaceuticals sector, BMI maintains the view that strong growth lies ahead, based on the rapidly growing population and emerging middle class, though high unemployment and low per capita spending, in addition to weak regulatory and intellectual property (IP) laws, are significant risks to the uptake of medicines in the country.
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948